CRISPR Therapeutics AG (CRSP) Net Cash Flow (2015 - 2026)

CRISPR Therapeutics AG has disclosed Net Cash Flow across 12 years of filings, most recently posting $72.3 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $72.3 million, up 214.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $184.6 million (up 139.09% YoY), and the FY2025 annual result was $49.2 million, up 153.91% from the prior year.
• Net Cash Flow came in at $72.3 million for Q1 2026 at CRISPR Therapeutics AG, up from $61.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $317.9 million in Q1 2024 to a low of -$286.4 million in Q4 2022.
• The 5-year median for Net Cash Flow is -$2.6 million (2022), against an average of -$29.9 million.
• Across the five-year window, Net Cash Flow sank 461.67% in 2022 and jumped 3243.38% in 2023, its largest moves.
• CRISPR Therapeutics AG's Net Cash Flow stood at -$286.4 million in 2022, then jumped by 51.61% to -$138.6 million in 2023, then jumped by 152.44% to $72.7 million in 2024, then dropped by 15.98% to $61.1 million in 2025, then rose by 18.36% to $72.3 million in 2026.
• The last three Net Cash Flow figures came in at $72.3 million (Q1 2026), $61.1 million (Q4 2025), and $92.9 million (Q3 2025), per Business Quant data.